Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 (Atibuclimab) in Acute Respiratory Distress Syndrome (ARDS)
NCT06513949Phase 2Recruiting
- Sponsor
- Implicit Bioscience
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing IC14 (atibuclimab) with Identical-appearing placebo (2 arms). Primary endpoint: Oxygenation Index at Day 4. Started Jun 2026; status: recruiting.
02
Drugs
atibuclimab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06513949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513949.